Aurobindo Pharma Unit I Receives US FDA Warning Letter

Eugia Pharma Specialities’ Unit I formulation facility received a US FDA Warning Letter following its prior Official Action Indicated status. Existing US supplies are unaffected, and the unit contributes approximately 2% of group revenue. Context: crystallizes the previously pending regulatory overhang.